Users consuming data from enterprise resources use Cognos as their main reporting tool for operational data. These videos are designed as both training tools, report training, and reference guides for ...

Making informed business decisions is made easier with Cognos’ intelligent interactive dashboards. A machine learning system and artificial intelligence technology are built into its system, ...

Cognos Business Intelligence is an IBM integrated business intelligence application that runs on the web. There are tools for reporting, analytics, scorecarding, and monitoring of events and metrics ...

INGLEWOOD, CA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cognos Therapeutics (“Cognos” and “the Company”), a leading innovator in medical technology, today proudly announced the formation of its Industry ...

A peer-reviewed scientific paper has gathered significant attention on the social media platform X (formerly Twitter), albeit for unfavorable reasons. If you’ve had any interaction with ChatGPT or ...

AI thrives on data but feeding it the right data is harder than it seems. As enterprises scale their AI initiatives, they face the challenge of managing diverse data pipelines, ensuring proximity to ...

In this challenging year for the hedge fund industry, the durability of small- to mid-sized funds comes into focus. While many larger funds can withstand ongoing market uncertainty, emerging managers ...

You know how you join into the Zoom call with six other people in it, and everyone goes around introducing themselves? Most introductions are absolutely horrible. Although I’m a notoriously hands-off ...

Cognos is a business intelligence and analytics software suite that was acquired by IBM in 2008. The software suite includes reporting, analysis, dashboards, and scorecards designed to help ...

Peter Gratton, Ph.D., is a New Orleans-based editor and professor with over 20 years of experience in investing, economics, and public policy. Peter began covering markets at Multex (Reuters) and has ...

Cognos Therapeutics is coming to the Nasdaq. The implantable drug delivery specialist has agreed to merge with Nocturne Acquisition Corp. to secure a spot on the stock exchange and boost its bank ...